echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Universal CAR-NK for relapsed/refractory B-cell lymphoma, 3/6 cases achieved CR

    Universal CAR-NK for relapsed/refractory B-cell lymphoma, 3/6 cases achieved CR

    • Last Update: 2022-05-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 25, U.


    On April 25, U.


    NKX019 is a CD19-targeting CAR-NK cell therapy from Nkarta and a "universal" CAR-NK cell therapy


    Lymphoma leukemia high-dose (10x10 8 CAR-NK cells, 3 infusions) group, of 6 evaluable patients: 5 achieved objective response (ORR=83%), 3 achieved complete response (CR=50%) , including one patient with diffuse large B-cell lymphoma and one patient with mantle cell tumor


    Likewise, no dose-limiting toxicities, as well as adverse events similar to the side effects of CAR-T


    CAR-T

    leaves a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.